Mutagenic evaluation of tromaril (N-beta-phenylethylanthranilic acid), a novel anti-inflammatory drug, using mammalian test systems.
The mutagenic effect of tromaril, a new anti-inflammatory drug, was assessed in Swiss male mice employing bone-marrow micronucleus induction, abnormal sperm formation, and the induction of meiotic chromosome anomalies in spermatocytes as the test parameters. Administration of tromaril induced significantly higher percentages of MN and abnormal sperm at 600 and 900 mg/kg body wt., whereas chromosomal anomalies in spermatocytes were significantly higher at all the 3 doses of 300, 600 and 900 mg/kg body wt. at time intervals of 7, 15 and 30 days as compared to parallel controls.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects; D002869:Chromosome Aberrations / Q000139:chemically induced; D025063:Chromosome Disorders; D004305:Dose-Response Relationship, Drug; D008297:Male; D008540:Meiosis / Q000187:drug effects; D051379:Mice; D009152:Mutagenicity Tests; D009153:Mutagens; D013094:Spermatozoa / Q000187:drug effects; D062367:ortho-Aminobenzoates / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D009153:Mutagens; D062367:ortho-Aminobenzoates; C019126:enfenamic acid